Scientists at The Scripps Research Institute (TSRI) in the US tethered HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus.
"This protection would be long term," said Jia Xie from The Scripps Research Institute (TSRI) in the US.
The technique offers a significant advantage over therapies where antibodies float freely in the bloodstream at a relatively low concentration.
Instead, antibodies in the new technique hang on to a cell's surface, blocking HIV from accessing a crucial cell receptor and spreading infection.
"You do not need to have so many molecules on one cell to be effective," he said.
Before testing their system against HIV, the scientists used rhinovirus (responsible for many cases of the common cold) as a model. They used a vector called lentivirus to deliver a new gene to cultured human cells.
This gene instructed cells to synthesise antibodies that bind with the human cell receptor (ICAM-1) that rhinovirus needs. With the antibodies monopolising that site, the virus cannot enter the cell to spread infection.
Since the delivery system cannot reach exactly 100 per cent of cells, the finished product was a mix of engineered and unengineered cells.
The researchers then added rhinovirus to these cell populations and waited to see what would happen.
The vast majority of cells died in about two days. In dishes with only unengineered cells, the population never recovered.
There was an initial die-off in the mixed engineered/unengineered populations, too, but their numbers quickly bounced back.
After 125 hours, these cell populations were back up to around the same levels as cells in an undiseased control group.
Cells without antibody protection died off, leaving protected cells to survive and multiply, passing on the protective gene to new cells.
This success led the researchers to test the same technique against HIV. To infect a person, all strains of HIV need to bind with a cell surface receptor called CD4.
The scientists tested antibodies that could potentially protect this receptor on the very immune cells normally killed by HIV.
After introducing cells to the virus, the researchers ended up with an HIV-resistant population. The antibodies recognised the CD4 binding site, blocking HIV from getting to the receptor.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
